首页>投融资
Effector Therapeutics
增发
eFFECTOR Therapeutics, Inc.是一家于2020年10月2日在特拉华州注册成立的公司。eFFECTOR是一家临床阶段的生物制药公司，专注于开拓一类被称为选择性翻译调节剂抑制剂(STRIs)的新型肿瘤药物的开发。
基本信息
-
公司全称eFFECTOR Therapeutics Inc
-
类型肿瘤药物研发商
-
产业领域药品研发/制造
-
公司人数15人以下
-
地址142 North Cedros Avenue Suite B Solana Beach CA 92075
-
联系电话858-925-8215
-
邮箱info@effector.com
-
成立时间2012-01-01
投融资
-
2023-06-08增发870万美元未透露
-
2023-05-31增发750万美元未透露
-
2021-08-26上市1.75亿美元未透露
-
2017-07-24C轮3860万美元Alexandria Venture InvestmentsSectoral Asset ManagementBioMed VenturesAstellas Venture Management辉瑞SR OneAltitude Life Science VenturesThe Column Group诺华AbingworthAbbVie Biotech VenturesU.S. Venture Partners
-
2016-02-19B+轮1600万美元Sectoral Asset Management
-
2015-12-22B轮4000万美元Astellas Venture ManagementOsage University PartnersAbingworthMission Bay CapitalThe Column GroupAltitude Life Science Ventures诺华SR OneAbbVie Biotech VenturesU.S. Venture Partners
-
2013-05-20A轮4500万美元Astellas Venture ManagementBill HarringtonSR OneOsage University PartnersMission Bay Capital诺华AbingworthU.S. Venture Partners
- 加载更多
相关投融资企业
收并购
Ipsen SA formerly the Beaufour-Ipsen Group, is a European pharmaceutical group founded in 1929. The group's research and development is targeted to the disease areas of endocrinology, oncology and neuromuscular disorders.In April 2011, Ipsen SA was nearing to completing a strategic review and planned to announce details in June of that year. In June 2011, the company announced restructuring plans in which it would restructure its business into four market-based franchises and focus its R&D on its peptide and tocin-based technologies. The company also planned to merge its R&D departments and close its Barcelona, Spain R&D center.The company planned to create four franchises: Endocrinology/Somatuline (lanreotide depot); Neurology/Dysport (abobotulinumtoxinA); Uro-oncology/Decapeptyl (triptorelin pamoate); and Hemophilia. It also planned to maximize the value of its short stature business, and this was to be managed directly by regions and countries. Ipsen also intended to to grow its primary care
战略投资
丹望医疗科技上海有限公司位于上海南翔精准医学产业园，致力于将最新的再生医学类器官技术临床转化，应用于疾病的诊疗、新药筛选、肿瘤标志物开发与鉴定，努力为临床提供个性化治疗的新技术，为新药研发提供精准、高效、优质的类器官模型。公司拥有全球领先的类器官技术创新平台，已建立了肺、胰腺、乳腺、胃、肠、肝等多个人体器官组织的类器官培养体系。
A轮
Ottimo Pharma是一家私营生物技术公司，由Medicxi和Jonny Finlay于2020年共同创立，专注于开发用于实体瘤的开创性创新癌症疗法。该公司的主导项目Jankistomig是一种PD1-VEGFR2双功能抗体，旨在通过单一IgG疗法同时靶向免疫检查点抑制和血管生成。通过推进这种双途径方法，Ottimo Pharma旨在改善癌症治疗结果，降低总体医疗负担。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息